For the hot flash symptom itself, the new drugs come reasonably close and work quickly, but standard-dose estrogen still produces a larger reduction in flashes than either new drug has matched against comparable placebo baselines, and no head-to-head trial exists between them.

Hormone therapy also treats bone loss and genitourinary symptoms at the same time, which the new nonhormonal drugs do not. The practical framing many clinicians use: these are the most effective nonhormonal drugs available and the clear first choice when hormones are contraindicated or declined, not a direct substitute for hormones.

What to know about this answer

Position 1 emphasizes that, for the symptom itself, the new drugs work quickly and meaningfully. Position 2 emphasizes that standard-dose estrogen's effect size is still larger and that hormone therapy provides bone and genitourinary benefits the new drugs do not.

What the research shows, and which source each finding rests on

Oral estrogen, with or without a progestogen, reduces weekly hot flush frequency by about 75 percent relative to placebo (weighted mean difference about -18 flushes/week; severity odds ratio 0.13), the basis for guidelines calling hormone therapy the most effective vasomotor symptom treatment

A[1]

Fezolinetant 45 mg reduced daily vasomotor symptom frequency by an additional 2.07 to 2.55 episodes versus placebo across its two pivotal phase 3 trials

B[2]B[3]

Elinzanetant 120 mg reduced daily moderate-to-severe vasomotor symptom frequency by an additional 3.2 episodes versus placebo in its twin pivotal phase 3 trials

D[4]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Effectively yes, for the symptom itself

Many prescribing menopause specialists, including Heather Hirsch

Onset is within a week, and placebo-adjusted reductions fall in a similar range to low-dose estradiol's margin in one head-to-head trial, plus sleep benefits especially with elinzanetant, all without hormone exposure.

B[5]D[4]

No, standard-dose estrogen's margin is still larger, and it treats more than flashes

Heather Hirsch (the other side of her own point) and Felice Gersh

Standard-dose estrogen's roughly 75 percent reduction versus placebo is a margin the new drugs have not matched against comparable baselines, there is no head-to-head trial, and hormone therapy simultaneously treats bone loss and genitourinary symptoms, which the nonhormonal drugs do not; Gersh argues that treating the hot flash alone while leaving the underlying hormone deficiency untreated is the deeper problem.

A[1]

What would settle it: A randomized head-to-head trial of an NK antagonist versus transdermal estradiol with vasomotor symptom, sleep, bone, and genitourinary endpoints. None exists as of August 2026.

What is really going on here

  1. Is the percent reduction from baseline, or versus placebo? A drug ad describing only the total change may be riding the placebo response; the placebo-adjusted number is the drug's real contribution.

Questions for your doctor

  1. Am I a candidate for hormone therapy, or is it contraindicated or something I'd rather avoid?
  2. If I choose a nonhormonal option, what am I not getting that hormone therapy would also provide, such as bone or genitourinary benefits?
  3. How do the expected effect sizes compare for my specific situation?
  4. Could we start with one option and reassess after a few months?

Questions with no answer yet

If a head-to-head trial directly compared one of the new nonhormonal drugs against transdermal estradiol, with vasomotor, sleep, bone, and genitourinary endpoints all measured together, would hormone therapy's advantage hold across all of them, or only some?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: This exact trial design is described as what would settle the debate, and none exists as of August 2026.

What would test it: The head-to-head randomized trial described above.

Is the roughly 75 percent reduction figure for standard-dose estrogen still the right benchmark to compare newer drugs against, given it comes from an older meta-analysis using different baseline populations than the newer drug trials?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The estrogen figure comes from a 2004 meta-analysis, while the newer drug figures come from trials run two decades later with different enrollment criteria, such as different minimum baseline flash frequency requirements, and there is no modern re-derivation of the estrogen benchmark using comparable trial populations.

What would test it: A modern trial or meta-analysis of estrogen using the same enrollment and outcome standards as the newer drug trials, to allow a fair comparison.

For women who cannot take hormones, does adding a bone-health or genitourinary-focused treatment alongside one of the new nonhormonal drugs close the gap with what hormone therapy would have provided?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Hormone therapy simultaneously treats bone loss and genitourinary symptoms while the nonhormonal drugs do not, but there is no report of a trial testing a combined nonhormonal strategy against hormone therapy as a whole-package comparison.

What would test it: A trial comparing a combined nonhormonal treatment package against hormone therapy across all of the domains hormone therapy is known to affect.

Sources

  1. 1.Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes.MacLennan AH et al., Cochrane Database Syst Rev 2004 · Systematic review or guideline
  2. 2.Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.Lederman S et al., Lancet 2023 · Randomised trial
  3. 3.Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.Johnson KA et al., J Clin Endocrinol Metab 2023 · Randomised trial
  4. 4.Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials.Pinkerton JV et al., JAMA 2024 · Comparative or small study
  5. 5.Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.Joffe H et al., JAMA Intern Med 2014 · Randomised trial

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides